Rio Ohmori's Contact Details

Rio Ohmori's Company Details

CellFiber Co., Ltd.

Bunkyo City, Tokyo, Japan • 3 Employees
Research

We create plug-and-play bio-manufacturing solutions using our unique cell culture platform technology, CellFiber™, to enable higher yields and product quality and ensure stability, predictability, reproducibility, and scalability of cells for cell and gene therapy applications. Our game-changing technology can dramatically lower costs of goods, development costs and timelines, and enable commercial viability. The CellFiber™ technology consists of hollow and permeable alginate hydrogel outer shells and a cell-rich core region. The core-shell microfibers protect from shear stress, control the thickness of cell aggregates produced and provide an easily removable covering. This ensures homogeneous and scalable 3D culture conditions. These characteristics can be used for:1. High-density cell culture2. Reducing cost of goods and footprint for manufacturing3. Scalable culture method from laboratory to commercial manufacturing for clinical use Thus far, we have been developing scale-up manufacturing processes for MSCs, iPSCs, T cells, NK cells, AAV vectors, and Lentiviral vectors. This platform-based development and manufacturing process disconnects production from specific products and will have an enormous impact on reducing development cost, timelines, and cost of goods, and will allow drug developers to significantly expand clinical pipelines in multiple therapeutic areas. We will work together with you for process development from the preclinical stage to improve your scale-up and cost reduction. We are looking for CMOs, CDMOs, therapeutic companies, pharmaceutical companies, and/or pharma manufacturing companies who need to improve cell culturing processes. We are currently developing GMP CellFiber™ Extruders and will be ready to support clinical and commercial manufacturing for any project. 日本語版Webサイトはこちらhttps://cellfiber.jp/